Joseph Mıkhael

14.7k total citations
204 papers, 4.8k citations indexed

About

Joseph Mıkhael is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Joseph Mıkhael has authored 204 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Hematology, 106 papers in Molecular Biology and 90 papers in Oncology. Recurrent topics in Joseph Mıkhael's work include Multiple Myeloma Research and Treatments (151 papers), Protein Degradation and Inhibitors (67 papers) and Peptidase Inhibition and Analysis (39 papers). Joseph Mıkhael is often cited by papers focused on Multiple Myeloma Research and Treatments (151 papers), Protein Degradation and Inhibitors (67 papers) and Peptidase Inhibition and Analysis (39 papers). Joseph Mıkhael collaborates with scholars based in United States, Canada and France. Joseph Mıkhael's co-authors include A. Keith Stewart, Rafaël Fonseca, Craig B. Reeder, P. Leif Bergsagel, Donna Reece, Martha Q. Lacy, Shaji Kumar, S. Vincent Rajkumar, Suzanne Trudel and Angela Dispenzieri and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Joseph Mıkhael

199 papers receiving 4.7k citations

Peers

Joseph Mıkhael
Vivek Roy United States
Brendan M. Weiss United States
Sikander Ailawadhi United States
Matthew F. Plevak United States
Heather J. Sutherland Canada
Amer M. Zeidan United States
Katja Weisel Germany
Sigurður Y. Kristinsson Sweden
Joseph Brandwein Canada
Amir T. Fathi United States
Vivek Roy United States
Joseph Mıkhael
Citations per year, relative to Joseph Mıkhael Joseph Mıkhael (= 1×) peers Vivek Roy

Countries citing papers authored by Joseph Mıkhael

Since Specialization
Citations

This map shows the geographic impact of Joseph Mıkhael's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Mıkhael with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Mıkhael more than expected).

Fields of papers citing papers by Joseph Mıkhael

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Mıkhael. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Mıkhael. The network helps show where Joseph Mıkhael may publish in the future.

Co-authorship network of co-authors of Joseph Mıkhael

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Mıkhael. A scholar is included among the top collaborators of Joseph Mıkhael based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Mıkhael. Joseph Mıkhael is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mıkhael, Joseph, et al.. (2025). Down with dex!. Blood. 145(1). 3–4. 1 indexed citations
2.
Landgren, Ola, Noa Biran, Elizabeth O’Donnell, et al.. (2025). Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma. HemaSphere. 9(7). e70178–e70178.
3.
Weisel, Katja, Meletios Α. Dimopoulos, Meral Beksaç, et al.. (2024). Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison. Leukemia & lymphoma. 65(4). 481–492. 3 indexed citations
4.
Richardson, Paul G., Aurore Perrot, Joseph Mıkhael, et al.. (2024). Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies. Blood Cancer Journal. 14(1). 209–209. 3 indexed citations
5.
Perrot, Aurore, Paul G. Richardson, Joseph Mıkhael, et al.. (2023). P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES. HemaSphere. 7(S3). e3398301–e3398301. 1 indexed citations
6.
7.
Auclair, Daniel, Carol Mansfield, Mark A. Fiala, et al.. (2022). Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States. SHILAP Revista de lepidopterología. 9 indexed citations
8.
Martin, Thomas G., Marcelo Capra, Mohamad Mohty, et al.. (2021). Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients Who Previously Underwent Transplantation: Ikema Subgroup Analysis. Transplantation and Cellular Therapy. 27(3). S65–S65. 2 indexed citations
9.
Martin, Thomas G., Joseph Mıkhael, Roman Hájek, et al.. (2020). Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. Blood. 136(Supplement 1). 7–8. 12 indexed citations
10.
Marshall, Ariela L., Sarah M. Jenkins, Amy S. Oxentenko, et al.. (2018). Internal medicine trainees' knowledge and confidence in using the American Society of Hematology Choosing Wisely guidelines in hemostasis, thrombosis, and non-malignant hematology. PLoS ONE. 13(5). e0197414–e0197414. 2 indexed citations
11.
Kaufman, Jonathan L., Cristina Gasparetto, Joseph Mıkhael, et al.. (2017). Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma. Blood. 130. 3131–3131. 12 indexed citations
12.
Richardson, Paul G., Joseph Mıkhael, Saad Z. Usmani, et al.. (2017). Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 130. 1887–1887. 3 indexed citations
13.
Auclair, Daniel, Carol Mansfield, Ajai Chari, et al.. (2017). Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach. Blood. 130. 5662–5662. 2 indexed citations
14.
Mıkhael, Joseph. (2016). Management of Carfilzomib-Associated Cardiac Adverse Events. Clinical Lymphoma Myeloma & Leukemia. 16(5). 241–245. 33 indexed citations
15.
Riva, Eloísa, et al.. (2015). Current imaging follow-up of non-Hodgkin lymphoma exposes patients to significant radiation but does not detect asymptomatic relapses. Leukemia & lymphoma. 57(6). 1363–1366. 2 indexed citations
16.
Mıkhael, Joseph, Steven R. Schuster, Víctor H. Jiménez‐Zepeda, et al.. (2012). Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 119(19). 4391–4394. 269 indexed citations
17.
Reeder, Craig B., Shaji Kumar, M. Q. Lacy, et al.. (2011). A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. British Journal of Haematology. 156(3). 326–333. 35 indexed citations
18.
Lacy, Martha Q., Suzanne R. Hayman, Morie A. Gertz, et al.. (2009). Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology. 27(30). 5008–5014. 226 indexed citations
19.
Reece, Donna, Christine Chen, Suzanne Trudel, et al.. (2008). Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology. 26(29). 4777–4783. 72 indexed citations
20.
Bredeson, Christopher, George Perry, Sheryl McDiarmid, et al.. (2002). Outpatient total body irradiation as a component of a comprehensive outpatient transplant program. Bone Marrow Transplantation. 29(8). 667–671. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vivek Roy Breakdown of academic impact, for papers by Brendan M. Weiss Breakdown of academic impact, for papers by Sikander Ailawadhi Breakdown of academic impact, for papers by Matthew F. Plevak Breakdown of academic impact, for papers by Heather J. Sutherland Breakdown of academic impact, for papers by Amer M. Zeidan Breakdown of academic impact, for papers by Katja Weisel Breakdown of academic impact, for papers by Sigurður Y. Kristinsson Breakdown of academic impact, for papers by Joseph Brandwein Breakdown of academic impact, for papers by Amir T. Fathi
Rankless by CCL
2026